March 8, 2007 -- Hollis-Eden Pharma was refused a contract by the HHS to supply radiation drug Neumune to the biodefense stockpile; LaJolla Pharma released positive data from a Phase III trial of Riquent for lupus; Barrier Therapeutics received approval to market Xolegel for seborrheic dermatitis in Canada; Myriad Genetics began a Phase II trial of Azixa in patients with brain cancer; Pfizer received FDA approval of five new indications for Lipitor; OncoGenex withdrew its application for an IPO; and Immune Response said the first patient in a Phase II trial received NeuroVax for MS. The Centient Biotech 200™ closed with a 10-point gain at 3828, a rise of .27%. More details...
